- Home
- FLYX vs ACIU Comparison
FLYX vs ACIU Comparison
Compare FLYX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- ACIU
- Stock Information
- Founded
- FLYX 2015
- ACIU 2003
- Country
- FLYX United States
- ACIU Switzerland
- Employees
- FLYX N/A
- ACIU N/A
- Industry
- FLYX Blank Checks
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- FLYX Finance
- ACIU Health Care
- Exchange
- FLYX Nasdaq
- ACIU Nasdaq
- Market Cap
- FLYX 264.1M
- ACIU 247.4M
- IPO Year
- FLYX N/A
- ACIU 2016
- Fundamental
- Price
- FLYX $3.20
- ACIU $1.89
- Analyst Decision
- FLYX
- ACIU Strong Buy
- Analyst Count
- FLYX 0
- ACIU 2
- Target Price
- FLYX N/A
- ACIU $12.00
- AVG Volume (30 Days)
- FLYX 12.2K
- ACIU 190.8K
- Earning Date
- FLYX 01-01-0001
- ACIU 03-13-2025
- Dividend Yield
- FLYX N/A
- ACIU N/A
- EPS Growth
- FLYX N/A
- ACIU N/A
- EPS
- FLYX N/A
- ACIU N/A
- Revenue
- FLYX $327,274,000.00
- ACIU $30,136,397.00
- Revenue This Year
- FLYX $35.08
- ACIU $120.91
- Revenue Next Year
- FLYX N/A
- ACIU $13.82
- P/E Ratio
- FLYX N/A
- ACIU N/A
- Revenue Growth
- FLYX 3.78
- ACIU 84.51
- 52 Week Low
- FLYX $1.79
- ACIU $1.77
- 52 Week High
- FLYX $8.39
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- FLYX 49.45
- ACIU 20.92
- Support Level
- FLYX $3.05
- ACIU $1.95
- Resistance Level
- FLYX $3.50
- ACIU $2.05
- Average True Range (ATR)
- FLYX 0.28
- ACIU 0.12
- MACD
- FLYX -0.00
- ACIU -0.03
- Stochastic Oscillator
- FLYX 37.74
- ACIU 4.10
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 90 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.